Real-world risk of new onset inflammatory bowel disease among psoriasis patients exposed to interleukin 17 inhibitors.

Abstract Background Information on real-world risk of inflammatory bowel disease (IBD) among interleukin-17 inhibitor (IL-17i) exposed psoriasis patients is limited. Objective To compare IBD risk in IL-17i exposed and unexposed psoriasis patients. Methods Retrospective cohort analysis of psoriasis patients with and without IL-17i exposure identified using electronic health records data. Primary outcomes were 6-month and 1-year IBD incidence. Results Crude 6-month IBD incidence was 0.16% (3/1,821) among psoriasis patients exposed to any IL-17i, 0.24% (3/1,246) among those exposed to secukinumab alone, and 0.11% (239/213,060) among those unexposed. Crude 1-year IBD incidence was 0.27% (5/1,821) among IL-17i exposed psoriasis patients, 0.32% (4/1,246) among those exposed to secukinumab alone, and 0.19% (412/213,060) among unexposed. In adjusted analysis, there was no significant difference in odds of developing IBD at 6-month (OR, 1.42; 95% CI, 0.45-4.43) and 1-year (OR, 1.37; 95% CI, 0.57-3.33) between exposed and unexposed psoriasis patients. Similarly, there was no significant difference in odds of developing IBD at 6-month and 1-year IBD between secukinumab exposed and unexposed psoriasis patients. Limitations Analysis may have been limited by low number of outcome events. Conclusion Incidence of IBD among psoriasis patients exposed to IL-17i is low and the risk appears similar to unexposed psoriasis patients.